Sentences with phrase «reduce heart failure»
«In everyday terms our findings suggest that consistently participating in the recommended 150 minutes of moderate to vigorous activity each week, such as brisk walking or biking, in middle age may be enough to reduce your heart failure risk by 31 percent,» study senior author Dr. Chiadi Ndumele said in a university news release.
http://www.health.com/
«Spironolactone reduces heart failure hospitalizations, but not mortality, study says.»
«Exercising more, sitting less reduces heart failure risk in men.»
Muscle damaged by heart attacks can be repaired by an injectable gel that forms scaffolding, attracting stem cells and blood vessels in a study that may lead to a new method for reducing heart failure.
In fact, light and moderate alcohol consumption both seem to have a variety of health benefits, including reduced heart failure risk, reduced heart attack risk, reduced stroke risk, reduced dementia risk, reduced diabetes risk... you get the picture.
Not exact matches
Since consumption of whole grain products and dietary fiber has been shown to reduce the risk of high blood pressure and heart attack, Harvard researchers decided to look at the effects of cereal consumption on heart failure risk and followed 21,376 participants in the Physicians Health Study over a period of 19.6 years.
Ensuring people diagnosed with diabetes are able to manage their diabetes effectively in order to reduce their risk of developing long term complications such as heart disease, stroke, kidney failure, blindness and amputation should also be the long term goal of the health service.
This together with a healthy lifestyle will reduce the chances of developing the long - term complications of diabetes such as blindness, heart disease, amputation, kidney failure and nerve damage.
In the U.S., one in five Medicare patients is readmitted to a hospital each year at an estimated cost of $ 17.5 billion annually.i To reduce this impact, the Affordable Care Act (ACA) has introduced hospital penalties based on readmissions conditions that commonly affect patients aged 65 and older — including acute myocardial infarction, congestive heart failure and pneumonia.i
Lifestyle and dietary modifications to maintain vascular health or reduce disease risk might help protect patients» heart health, but there are currently limited diet - based therapeutic approaches to counteract cardiovascular disease in patients with kidney failure.
The rationale for using spironolactone - an inexpensive, generic, medication - stems from the pioneering research of Bertram Pitt, MD, University of Michigan School of Medicine, who showed the benefit of this class of drugs in patients with heart failure and reduced ejection fraction, and who also served as chair of the TOPCAT Steering Committee.
A late - breaking clinical trial, known as the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump functHeart Failure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump funFailure with an Aldosterone Antagonist (TOPCAT) trial, to be presented at the American Heart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump functHeart Association (AHA) Scientific Sessions, November 18, 2013, demonstrates that spironolactone did not reduce the primary outcome of cardiovascular death, heart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump functheart failure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump funfailure hospitalization, nor surviving a cardiac arrest in patients with heart failure and preserved ejection fraction (pump functheart failure and preserved ejection fraction (pump funfailure and preserved ejection fraction (pump function).
However, spironolactone did reduce the major burden faced by these patients - the risk of repeated hospitalizations for heart failure.
«Our study suggests that in patients with heart failure and atrial fibrillation, catheter ablation is an effective alternative treatment that can help patients avoid or discontinue this drug to reduce the risk of these long - term side effects.»
Professor Philip Eaton, Professor of Cardiovascular Biochemistry at King's College London, said: «The findings of our study help to explain why previous research has shown that a Mediterranean diet supplemented with extra-virgin olive oil or nuts can reduce the incidence of cardiovascular problems like stroke, heart failure and heart attacks.»
The findings published in the New England Journal of Medicine found the drug canagliflozin reduced the overall risk of cardiovascular disease by 14 per cent and reduced the risk of heart failure hospitalisation by 33 per cent.
The current study was designed to investigate whether the kind of significant weight loss that usually results from bariatric surgery reduces the risk of heart failure exacerbation.
They found that deaths, repeat heart attacks, heart failure admissions and strokes were all significantly reduced among patients who'd been diagnosed.
Beta - blockers block the effects of adrenaline on the heart, reduce irregular heartbeat (arrhythmia) and help prevent heart failure.
Serelaxin reduces the occurrence of in - hospital worsening heart failure by almost half in patients admitted for acute heart failure, according to the RELAX - AHF trial.
Improvement in the initial signs and symptoms of heart failure, as well as reduced mortality, has already been reported with serelaxin from the RELAX - AHF trial.
«Serelaxin reduces in - hospital worsening heart failure, study suggests.»
Findings from the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of HeHeart Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Failure with an Aldosterone Antagonist (TOPCAT) trial, have revealed that adding the medication known as spironolactone (Aldactone) to existing therapy did not significantly reduce the composite time to either death from cardiovascular causes, surviving a cardiac arrest, or hospitalization to manage heart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Heheart failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of failure in patients with heart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of Heheart failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of failure and a preserved ejection fraction in a study funded by the National Heart, Lung and Blood Institute, National Institutes of HeHeart, Lung and Blood Institute, National Institutes of Health.
Iron deficiency is present in approximately 50 percent of patients with heart failure with reduced left ventricular ejection fraction (HFrEF; ejection fraction: a measure of how well the left ventricle of the heart pumps with each contraction) and is associated with reduced functional capacity, poorer quality of life, and increased mortality.
«If clinicians decide to prescribe spironolactone to their patients to reduce their risk of being hospitalized for heart failure, there is an associated responsibility to monitor for serum markers of kidney and electrolyte disorders which can be exacerbated by spironolactone.»
We get heavily hyped drugs like Avastin, which shrank tumors without adding significant time to cancer patients» lives (and increased the incidence of heart failure and blood clots to boot); Avandia, which lowered blood sugar in diabetics but raised the average risk of heart attack by 43 percent; torcetrapib, which raised both good cholesterol and death rates; and Flurizan, which reduced brain plaque but failed to slow the cognitive ravages of Alzheimer's disease before trials were finally halted in 2008.
«AF is also associated with increased mortality, reduced quality of life and a higher risk of heart failure.»
Upon analyzing the different types of activities, certain types of physical activity were associated with reduced risk of heart failure such as walking and bicycling or exercising more than one hour per week.
Our findings suggest that efficient IBD treatment aimed at reducing the length and number of disease activity episodes might lower the risk of heart failure.»
A large randomized controlled trial of ischemic postconditioning in patients who had experienced the deadliest form of heart attack — ST - segment elevation myocardial infarction (STEMI)-- failed to show that this procedure significantly reduces death from any cause or hospitalization for heart failure, according to research presented at the American College of Cardiology's 65th Annual Scientific Session.
«An incredible amount of expensive and time - consuming resources are being spent on reducing readmissions at a national level, but have not translated into a reduction in heart failure mortality,» said senior author Flora Sam, MD, associate professor of cardiovascular medicine at the Whitaker Cardiovascular Institute at BUSM and attending physician of cardiovascular medicine and heart failure at BMC.
Early treatment with metoprolol treatment also significantly reduced the rate of hospital readmission for chronic heart failure, and massively reduced the need to implant a cardioverter - defibrillator.
Exploring medicinal treatment options for diastolic heart failure patients could potentially reduce readmissions, morbidity, mortality and long - term healthcare costs,» said Sam.
The DANAMI -3-DEFER trial was the largest trial yet conducted to evaluate whether delaying stent implantation would improve patients» survival and reduce their risk of heart failure or another heart attack.
Borja Ibáñez — joint lead investigator on the study with Valentín Fuster — explains that «the possibility to reduce so dramatically the number of cases of chronic heart failure (with all the associated treatments and hospital readmissions) with such a cheap procedure (the metoprolol treatment costs less than two euros per patient) could generate enormous savings for health services across Europe.»
A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long - term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as «diastolic heart failure» and congestive heart failure with reduced ejection fraction also known as «systolic heart failure.»
Delayed or deferred stent implantation in patients experiencing the deadliest form of heart attack — ST - segment elevation myocardial infarction (STEMI)-- failed to reduce death from any cause, hospitalization for heart failure, subsequent heart attacks or the need for a repeat procedure to restore blood flow to the heart, researchers reported at the American College of Cardiology's 65th Annual Scientific Session.
The observed pattern of the reduced genera and families of bacteria seems very characteristic of heart failure, which is why these results may be new points of departure for therapies.
An analysis of the clinical trials suggests that ACEIs reduce the risk of death from all causes by 13 percent, cut the risk CV deaths by 17 percent and lower the risk of major CV events by 14 percent, including myocardial infarction (heart attack) by 21 percent and heart failure by 19 percent.
The 10 - year Warfarin and Aspirin for Reduced Cardiac Ejection Fraction (WARCEF) trial is the largest randomized, double - blind comparison of aspirin and warfarin (also known by its brand name Coumadin) for heart failure, following 2,305 heart failure patients whose heart muscle pumps less oxygen - rich blood into the body, known as reduced ejection fraction, at 168 study sites in 11 countries on three contReduced Cardiac Ejection Fraction (WARCEF) trial is the largest randomized, double - blind comparison of aspirin and warfarin (also known by its brand name Coumadin) for heart failure, following 2,305 heart failure patients whose heart muscle pumps less oxygen - rich blood into the body, known as reduced ejection fraction, at 168 study sites in 11 countries on three contreduced ejection fraction, at 168 study sites in 11 countries on three continents.
«If patients know they have received a drug treatment that might increase their risk of heart failure, it's even more important to take care of the aspects of their life that they can control to reduce their risk as much as possible and to work with their medical care team to detect issues as early as possible,» Larsen said.
«Our observational study found that treating to low pressures doesn't provide any benefit to patients with regard to reducing risk of dangerous heart events like heart attack, heart failure and stroke.
Medicare and Medicaid reimbursements will be reduced under provisions of the Affordable Care Act for hospitalized conditions such as heart failure, so it is imperative for hospitals to consider how cost reductions may influence the quality of care for vulnerable populations.
Current treatments for heart failure come in the form of medications like ACE inhibitors, beta blockers, and diuretics to reduce fluid buildup.
Non-Ischemic Heart Failure With Reduced Ejection Fraction Is Associated With Altered Intestinal Microbiota — Themistoklis Katsimichas — Circulation Journal
Results of one of the largest studies of heart failure to date show that warfarin is no better than aspirin in reducing the combined risks of brain hemorrhage, stroke and death in most heart failure patients.
Non-Ischemic Heart Failure With Reduced Ejection Fraction Is Associated With Altered Intestinal Microbiota
In previous research, finerenone reduced albuminuria in pa ¬ tients with chronic kidney disease and heart failure, with a lower incidence of hyperkalemia (higher than normal levels of potassium in the blood) compared to another medication.
In large animal models of heart failure, the researchers found that gene therapy delivery of high dose SUMO - 1 alone, as well as SUMO - 1 and SERCA2 together, result in stronger heart contractions, better blood flow, and reduced heart volumes, compared to just SERCA2 gene therapy alone.
While it is true that this condition itself can not be cured, heart failure symptoms themselves can be managed and reduced or improved with stem cell therapy.